Pelvic lipomatosis

Summary

Pelvic lipomatosis (MONDO:0006593) is a disease and 1 clinical trial. A subtype of lipomatosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pelvic lipomatosis
Mondo ID	MONDO:0006593
EFO	EFO:1000748
MeSH	C535549
DOID	DOID:3927
NCIT	C27486
UMLS	C0406608
MedGen	96064
Is cancer (heuristic)	no

Also known as: Excess of mature unencapsulated fatty tissue in the pelvis · pelvic lipomatosis · pelvic lipomatosis (morphologic abnormality)

Disease family

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign connective and soft tissue neoplasm › benign lipomatous neoplasm › lipomatosis › pelvic lipomatosis

Related subtypes (8): diffuse lipomatosis, mediastinal lipomatosis, steroid lipomatosis, adiposis dolorosa, multiple symmetric lipomatosis, encephalocraniocutaneous lipomatosis, congenital infiltrating lipomatosis of the face, pancreatic lipomatosis duodenal stenosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07530627	PHASE1	COMPLETED	Efficacy of UMT in CG Patients With PL